2 Clarke Drive
Cranbury, NJ 08512
© 2022 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Daniel Sherbenou, MD, PhD, discusses future directions with maintenance therapy in patients with relapsed/refractory multiple myeloma who received CAR T-cell therapy.
Daniel Sherbenou, MD, PhD, associate professor, Division of Hematology, University of Colorado (UC) Health’s Blood Disorders and Cell Therapies Center, UC Medicine, discusses future directions with maintenance therapy in patients with relapsed/refractory multiple myeloma who received CAR T-cell therapy.
Optimization of maintenance therapy in the post–CAR T-cell therapy setting for patients with multiple myeloma is an evolving area of research, Sherbenou says. Moreover, understanding resistance to CAR T-cell therapy and what therapy to give following progression on CAR T-cell therapy are important research efforts.
It may be that flexible combination regimens that are not built with proteasome inhibitor– or immunomodulatory agent–backbones will have utility in the post–CAR T-cell therapy setting, Sherbenou explains. Moreover, minimal residual disease status may guide adjustments to maintenance therapy selection in this patient population, Sherbenou concludes.